Eap C B, Koeb L, Holsboer-Trachsler E, Baumann P
Département Universitaire de Psychiatrie Adulte (DUPA), Hôpital de Cery, Lausanne, Switzerland.
Ther Drug Monit. 1992 Oct;14(5):380-5. doi: 10.1097/00007691-199210000-00007.
A two-step high-performance liquid chromatography method is described, using a CN column and an alpha 1-acid glycoprotein column, which allows the measurement of the enantiomers of the hydroxy metabolites of trimipramine in plasma of trimipramine-treated patients. Of the four patients analyzed, three showed approximately equimolar concentrations of the (D)- and (L)-enantiomers of the hydroxy metabolites (2-hydroxy-trimipramine and 2-hydroxy desmethyltrimipramine), and one was found to have roughly twice as much of the (L)-form and of the (D)-form of 2-hydroxy trimipramine and 2-hydroxy desmethyltrimipramine. From the data available on the pharmacological effects of the enantiomers of trimipramine, it is postulated that this interindividual variability in its pharmacokinetics is another factor that could contribute to the interindividual variability in its pharmacodynamics.
本文描述了一种两步高效液相色谱法,该方法使用氰基柱和α1-酸性糖蛋白柱,可用于测定经曲米帕明治疗患者血浆中曲米帕明羟基代谢物的对映体。在所分析的4例患者中,3例患者的羟基代谢物(2-羟基曲米帕明和2-羟基去甲曲米帕明)的(D)-和(L)-对映体浓度大致相等,而另1例患者的2-羟基曲米帕明和2-羟基去甲曲米帕明的(L)-型和(D)-型含量约为前者的两倍。根据曲米帕明对映体药理作用的现有数据推测,其药代动力学的个体间差异是导致其药效学个体间差异的另一个因素。